Grand Slam wall may not derail Sun's offer to take Taro private, say analysts
This article was originally published in Scrip
Grand Slam Asset Management has opposed Sun Pharmaceutical Industries' sweetened offer price for the remaining 34% of Taro Pharmaceutical Industries not held by Sun in Taro, though some analysts say that it is unlikely to completely derail the Indian firm's plans based on Sun's voting might and potential backing of other minority shareholders.
You may also be interested in...
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.